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Highlights 
 PARP enzymes regulate metabolic transcription factors and energy sensor systems. 
 PARP-1 and PARP-2 regulate mitochondrial oxidation. 
 PARPs are involved in higher order metabolic regulation and in the pathogenesis of 
metabolic diseases. 
 
 
 
 
 
 
Abstract 
Poly(ADP-ribosyl)ation (PARylation) is an evolutionarily conserved reaction that had been 
associated with numerous cellular processes such as DNA repair, protein turnover, 
inflammatory regulation, aging or metabolic regulation. The metabolic regulatory tasks of 
poly(ADP-ribose) polymerases (PARPs) are complex, it is based on the regulation of 
metabolic transcription factors (e.g. SIRT1, nuclear receptors, SREBPs) and certain cellular 
energy sensors. PARP over-activation can cause damage to mitochondrial terminal 
oxidation, while the inhibition of PARP-1 or PARP-2 can induce mitochondrial oxidation by 
enhancing the mitotropic tone of gene transcription and signal transduction. These PARP-
mediated processes impact on higher order metabolic regulation that modulates lipid 
metabolism, circadian oscillations and insulin secretion and signaling. PARP-1, PARP-2 and 
PARP-7 are related to metabolic diseases such as diabetes, alcoholic and non-alcoholic fatty 
liver disease (AFLD, NAFLD), or on a broader perspective to Warburg metabolism in cancer 
or the metabolic diseases accompanying aging. 
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1. The biochemistry and enzymology of PARPs 
Seventeen multidomain proteins belong to the PARP family in humans, all members 
share the PARP domain, responsible for catalytic activity[1]. PARPs contain other functional 
units serving DNA or RNA binding (e.g. zinc fingers), signals that define their cellular 
localization (e.g. nuclear localization signal) or domains that enable protein-protein 
interaction, auto-poly(ADP-ribosyl)ation (PARylation) and interaction with ADP-ribose 
(ADPR) mono and polymers [1]. 
PARP-1, the first described PARP enzyme, is able to PARylate proteins. On the course 
of the reaction NAD+ is hydrolyzed into ADPR and nicotinamide. ADPR is then joined to 
glutamate, aspartate and lysine residues of acceptor proteins that is termed initiation and is 
followed by elongation or branching steps [2]. PAR has a short half-life due to rapid and 
efficient degradation by poly(ADP-ribose) glycohydrolase (PARG), ADP-ribosyl-acceptor 
hydrolase 3 (ARH3), ADP-ribosyl lyase and macrodomain containing proteins to ADPR[3]. 
ADPR is further degraded by nucleoside diphosphate linked to X (NUDIX) pyrophosphatases 
to ADP[4]. The major PAR-containing cellular compartment is the nucleus and to a lower 
extent the cytosol, while the presence of PAR in the mitochondria remains a debated issue 
[5, 6]. About 85-90% of PARP activity is related to PARP-1 while PARP-2 contributes to 
about 10-15% [7], only the remaining minority is covered by other members of the family. It 
should be noted also that mono or oligo-ADP-ribose on target proteins can be further 
elongated by PARylating PARPs[8]. There are several PARP inhibitors (PARPi's) in use for 
the blockade of PARPs, one of them, olaparib (AZD-2281, Lynparza) is now in clinical use. 
Most of these inhibitors are not isoform selective[9]. It is of note that there are natural 
inhibitors of PARPs such as niacin (vitamin B3) that is cleaved off NAD+ upon PARP 
activation or may stem from external source or fully external ones, like flavones, caffeine or 
theobromine [2, 10-12]. 
PARPs are best known for their activation upon DNA damage, however only PARP-1, 
PARP-2 and PARP-3 are DNA damage-dependent [13]. Besides DNA damage, PARPs are 
regulated through a wide array of posttranslational modifications such as ubiquitination, 
phosphorylation or acetylation, interaction with protein cofactors and through the modulation 
of their expression via miRNAs (PARP-1 by miRNA223; PARP-2 by miRNA149)[3, 14, 15]. It 
is a current endeavor to identify the methodology for the assessment of the PARylated 
proteins (the PARylome) with high throughput methods [16-18], however, there are already 
several hundreds of proteins identified in the 50 years history of PARylation (see the public 
database at ADPriboDB.leunglab.org). 
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There are several tasks in the cells performed or regulated by PARPs, in the current 
review we will focus on their role in metabolic regulation. For all other functions we refer the 
readers to recent thorough reviews on the topic[3, 14, 15]. 
 
2. PARPs in the transcriptional regulation of metabolism 
PARP enzymes are deeply involved in transcriptional regulation. The best characterized 
member, PARP-1, may modulate chromatin through regulating DNA methylation, chromatin 
marks and chromatin composition (e.g. exchange between H1 and PARP-1) [14]. Also, 
independently of its catalytic activities PARP-1 may act as a scaffolding protein and may be 
involved in the recruitment of other coregulatory enzymes [14]. Whether PARP activity is 
necessary to accomplish these regulatory tasks varies between the individual cases. 
Another possibility for transcriptional regulation is the interaction between PARPs and 
transcription (co)factors. PARPs were shown to interact with numerous metabolic 
transcription factors. The available information on the interaction between PARPs and most 
of these transcription factors is limited to the validation of interaction and the identification of 
a few targets (e.g. nuclear respiratory factor (NRF)-1 and NRF-2 that interact with PARP-
1)[5].Below those interactions will be detailed where more information is available on the 
molecular mechanism. 
 
2.1  Interactions between PARPs and Sirtuins 
PARP-1, -2 and -7 were shown to interact with sirtuins[2]. Sirtuins (SIRT1-7) are NAD+-
dependent protein deacylase enzymes with widespread metabolic and anti-aging properties. 
Sirtuins can deacylate (frequently deacetylate) target proteins at the expense of cleaving an 
NAD+ molecule that is a common biochemical feature with PARPs [2]. The seven members 
of the sirtuin family can be found in all compartments of cells, generally nuclear (SIRT1, 
SIRT6, SIRT7), cytosolic (SIRT1, SIRT2) and mitochondrial (SIRT3, SIRT4, SIRT5) sirtuins 
are distinguished. The acyl group is coupled to ADP-ribose creating O-acyl-ADP-ribose. 
SIRT4 and SIRT6 were shown to exert NAD+-dependent mono-ADP-ribosyltransferase 
activity[2]. Sirtuins preferentially act as transcriptional cofactors[2]. 
There are several levels of the interaction between PARPs and sirtuins. First, those 
PARP and sirtuin enzymes that are present in the same compartment may compete for the 
common NAD+ substrate. PARP-1 binds and cleaves NAD+ more readily than SIRT1 (KM 
PARP-1<KM SIRT1, vmax PARP-1>vmax SIRT1), while the substrate binding and cleaving properties of 
PARP-2 and SIRT1 fall into the same range (KM PARP-2~KM SIRT1, vmax PARP-2~vmax SIRT1)[2]. In 
other words, when PARP-1 is activated it can easily outcompete SIRT1 for the common 
substrate. Since PARP-1 is activated in all cells to a certain extent, the deletion of PARP-1 
induces NAD+ levels that in turn may switch on SIRT1. Importantly, the deletion of PARP-1 
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does not affect the activity of cytoplasmic SIRT2 or mitochondrial SIRT3 suggesting 
compartment-specific effects of PARP-1 deletion[2]. The application of PARP inhibitors 
phenocopy PARP-1 deletion[2].Interestingly, tankyrase activity depends on cellular NAD+ 
production, a phenomenon yet without physiological roles [19]. 
Posttranslational modifications represent another level of interaction. PARP-1 is an 
acetylated protein that is active when acetylated [20]. Rajamohan and colleagues [20] 
showed that pharmacological activation of SIRT1 leads to the deacetylation and inhibition of 
PARP-1. Yet no studies have shown that PARP-1 could PARylate SIRT1 and hence 
modulate SIRT1 activity. 
Activation of SIRT1 upon the deletion of PARP-1 is characteristic for the brown adipose 
tissue and skeletal muscle and leads to mitochondrial biogenesis[2]. 
The deletion of PARP-2 also leads to increases in SIRT1 activity. It was likely that the 
deletion of PARP-2 could also increase NAD+ levels, similarly to the deletion of PARP-1. 
However, in our study [21] NAD+ did not increase equivocally in all models calling for an 
alternative route. We found that PARP-2 acts as a repressor of SIRT1 expression and 
concludedthat decreases in the expression of PARP-2 enhance SIRT1 expression and 
activity. This hypothesis has been challenged by a study [22] showing that transient SIRT1 
overexpression does not enhance mitochondrial biogenesis. In fact, a third study by 
Mohamed and colleagues [23] showed consistent increases in NAD+ upon PARP-2 ablation 
making it more likely that PARP-2 and SIRT1 can be also interconnected through changes in 
NAD+ levels on the top of the regulation of SIRT1 expression. PARP-1 does not affect the 
expression of SIRT1[2, 24]. Activation of SIRT1 upon the deletion of PARP-2 is characteristic 
for the liver and skeletal muscle and leads to mitochondrial biogenesis in these tissues[2]. 
Typical targets of SIRT1 comprise transcription factors such as PGC-1α, FOXO1 or p53 
that are activated upon deacetylation and declutch gene expression programs culminating in 
mitochondrial biogenesis [2]. It should be noted that the physiological effects of the PARP-
sirtuin interaction is not limited to metabolic implications but (among others) cardiovascular 
and neurological pathologies are also mediated in that pathway (for review see [2]).  
 
2.2 Interactions between PARPs and nuclear receptors 
Nuclear receptors (NR) are transcription factors that are usually activated by lipophilic 
ligands [25]. NRs regulate an immense number of metabolic processes, as several hormone 
and metabolite receptors can be found among NRs. NRs work in dimers and require the 
presence of interacting proteins that form a complex over the NR and the neighboring 
chromatin. The composition of that complex changes as a function of the ligand binding of 
the NR changing between an activated state and a repressed state. Proteins that facilitate 
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NR activation are called co-activators, while those bringing about NR repression are called 
co-repressors; nevertheless, there are constitutive protein members of the complex too. 
PARP-1, -2 and -7 enzymes had been shown to be involved in NR regulation (Table 1). 
PARP-1 is known to functionally and physically interact with both homodimeric (estrogen 
receptor (ER), progesterone receptor (PR)) and heterodimeric/orphan nuclear receptors 
(retinoic acid receptor (RAR), retinoic X receptor (RXR), thyroid hormone receptor (TR), 
peroxisome proliferators activated receptor family (PPARs), NR4A family (NOR1, Nurr1, 
Nurr7))[5]. PARP-1 predominantly binds to nuclear receptors through the second zinc finger 
of the DNA binding domain, however, direct binding of PARPs to DNA seems to be also 
important for the NR – PARP interaction[5]. 
In the case of the RXR/TR [26], liver X receptor (LXR) [27] and NOR-1 [28] PARP-1 
activation has been reported to repress transcriptional activity. In contrast to that, activation 
through PARPs is also possible, PARP-7 can mono-ADP-ribosylate and activate LXR, while 
upon ERα activation PARP-1 is necessary for the recruitment of topoisomerase IIβ[29]. The 
role of PARP-1 in PPAR activation is inconsistent, PARP-1 overactivation can abrogate 
PPARγ activity [30], while other studies showed that in the absence of PARP-1 PPARγ 
activity is reduced [31, 32]. 
 
2.3  Interactions between PARP-2 and sterol-regulated element binding proteins 
(SREBPs) 
Sterol-regulated element binding proteins SREBP-1 and SREBP-2 are cholesterol-sensitive 
transcription factors responsible for cholesterol and fatty acid (FA) import and synthesis [33, 
34]. SREBP-1 and –2 reside in the Golgi apparatus until cellular cholesterol levels drop that 
activates proteases that can process SREBPs. Upon activation the membrane-bound 
SREBPs undergo multiple proteolytic cleavage. The resulting processed, active SREBPs 
translocate to the nucleus, where they bind to promoters of HMGCS, HMGCR, LDLR, FDPS, 
cytochrome P450, cyp51A1, SCD, ACACA, FASN, ACLY, PPARγ and ME2 [33, 34]. The 
protein products of these genes induce cholesterol and FA biosynthesis. PARP-2 is a 
suppressor of the promoter of SREBP-1 through directly binding to promoter DNA, therefore 
the ablation of PARP-2 induces SREBP1 mRNA and protein expression[35]. Furthermore, in 
PARP-2 silenced hepatocytes the ratio between nuclear SREBP1/cytosolic SREBP1 
increases through an unknown mechanism further enhancing SREBP1-mediated 
transcription [35]. 
 
2.4  Interaction of PARPs with other metabolic transcription factors 
Although less characterized in terms of physiological outcomes, PARP-1 was shown to 
interact with other metabolic transcription factors, such as NRF-1, hypoxia-inducible factor 
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(HIF)-1 and -2 and p53. PARP-1 is necessary for the hypoxia-inducible factor (HIF)-1 
mediated depression of mitochondrial complex II and IV and hence facilitates the down-
regulation of mitochondrial activity. Interestingly, when PARPs are inhibited 
pharmacologically, HIF-1 activation is maintained longer, prolonging release from hypoxic 
accommodation [5]. Besides HIF-1, PARP-1 is a cofactor of HIF-2 and exert similar functions 
when in complex with HIF-1 [5].PARP-1 is a positive cofactor of NRF-1, a transcriptional 
cofactor that, when activated, can enhance the transcription of, among others, PGC-1α or 
PGC-1β that are positive regulators of mitochondrial activity[5]. PARP-1 mediated activation 
of NRF-1 can be vital upon return from PARP-1 mediated depression of mitochondrial 
oxidation [5]. 
 
3 Relationship of PARPs and energy sensor systems 
Cellular and organismal metabolism is regulated by a set of signal transduction 
pathways that translate environmental stimuli into metabolic responses. PARPs were shown 
to interfere with phosphatidylinositol 3-kinase (PI3K)–Akt–glycogen synthase kinase-3 
(GSK3) and AMP activated kinase (AMPK) pathways [36, 37]. 
The activation of the PI3K – Akt pathway support mitochondrial activity and prevents 
mitochondrial transition pore opening, furthermore that pathway has pivotal role in the signal 
transduction events following the activation of certain tyrosine kinases such as the insulin 
receptor. The application of PARP inhibitors increased the activity of PI3Kand Akt [36, 38]. 
Tankyrases (PARP-5a, PARP-5b) were also shown to regulate GSK3 and the PI3K[15]. 
AMPK is an energy sensor of cells that is activated by low ATP and high AMP levels (i.e. 
high AMP/ATP ratio). AMPK activation increases upon PARP-1 activation [39]. AMPK can 
phosphorylate and activate PARP-1 [37, 40]. AMPK and PARP-1 can mutually activate each 
other bringing about a feed forward loop. Furthermore, PARP-1 was shown to interact with 
the mechanistic target of rapamycin (mTOR) upon autophagy[41]. The activity of AMPK and 
mTOR is inversely related [42]. However, it remains an open question what is the 
relationship between the activation of mTOR AMPK and PARP-1. 
 
4 Interplay of PARPs with mitochondrial homeostasis 
The first observation in conjunction with PARPs and mitochondria was the devastating 
effects of PARP-1 overactivation upon excessive DNA damage on mitochondrial oxidative 
metabolism [43]. It is characterized by the loss of mitochondrial membrane potential, reduced 
activity of mitochondrial complex I, reduced mitochondrial oxidation and ATP production, 
superoxide production and the destruction of mitochondrial architecture[5]. PARP-1 
activation opens mitochondrial transition pores (MTPs) promoting the release of 
mitochondrial content [43]. When MTPs are open cytochrome c, caspases and apoptosis 
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inducing factor (AIF) can leave the mitochondria [15, 44]. Later studies have shown that 
PARP activation impairs mitochondrial quality control as well, such as the mitochondrial 
unfolded protein response [45] and mitophagy [46].Apparently, PARP-2 also participates in 
these processes, as the deletion of PARP-2 enhances mitochondrial activity [21, 23, 47]. 
At the molecular level several parallel pathways culminate in mitochondrial dysfunction 
upon PARP-1 overactivation. Berger and colleagues [48] suggested that cellular NAD+ levels 
are largely consumed upon PARP overactivation and consequently, NAD+ resynthesis 
depletes cellular energy reserves that then forces cells into a metabolic collapse. In addition 
to that, several mitotropic transcription factors are inhibited upon PARP activation (e.g. Sirt1), 
HIF is stabilized and the PI3K-Akt pathway is inhibited that suppress mitochondrial oxidative 
function on the long run. It should be also noted that PARP overactivation equally slows 
down glycolytic flux as well [5]. 
PAR molecules that are cleaved off from PARylated proteins and transported into the 
cytosol can also hamper mitochondrial oxidation. PAR can bind to the mitochondrial 
membrane declutching MTP opening[49] and can dissociate hexokinase from the 
mitochondrial surface uncoupling glycolysis and mitochondrial energy production 
[50].Furthermore, degradation of PAR by NUDIX pyrophosphates[5] yields AMP and can be 
transported into the cytosol. AMP then can block adenine nucleotide translocase (ANT) in the 
mitochondrial membrane slowing down mitochondrial energy production[5].Mitochondrial 
uncoupling leads to oxidative stress[43] that may have secondary inhibitory effects on 
mitochondrial enzymes [51]. 
A highly debated issue in the PARP field is the existence of an intrinsic PARP activity in 
the mitochondria. High NAD+ levels and enzymes for PAR degradation undoubtedly exist in 
the mitochondria, however, yet the presence of PARP activity is doubtful[5]. A recent study 
involving proximity ligation assays have provided evidence for the mitochondrial presence of 
PARP-1 and PAR and suggest a different timing for mitochondrial PARP-1 activation as 
compared to nuclear PARP-1 activation upon genotoxic stress[52]. For an in-depth review on 
the pros and cons of mitochondrial PARylation we refer the reader to a recent review [6]. 
PARP-mediated mitochondrial damage can serve as a trigger for cell death programs. It 
seems clear that PARP overactivation through depleting cellular energy stores makes it 
impossible to execute energy intensive cell death pathways such as the classical caspase-
mediated apoptosis, but declutches necrosis or necroptosis[15]. In fact, during apoptosis 
PARP-1, PARP-2 and PARG are cleaved by caspases presumably to save energy to 
complete apoptosis and in line with that, PARP inhibition can convert necrotic processes into 
apoptosis as demonstrated on a large set of models[15]. Fatokun et al [53]have defined a 
PARylation-dependent mode of cell death characterized by enhanced nuclear PARylation, 
AIF translocation to the nucleus and the lack of caspase activation, coined parthanatos. 
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Genetic or pharmacological PARP inhibition can enhance mitochondrial energy 
production in contrast to PARP overactivation. Not only are the above deleterious processes 
reversed by PARP inhibition but pathways kick off that actively enhance mitochondrial 
oxidative metabolism such as AMPK activation by the AMP derived from PAR[5], activation 
of SIRT1[5], the activation of the PI3K-Akt [36] pathway or the improvement of mitochondrial 
unfolded protein response[45]. 
 
5 PARPs in higher order metabolic regulation 
5.1  Regulatory role of PARPs in lipid metabolism 
Despite the lack of comprehensive studies, our current knowledge strongly suggests that 
PARPs are intricately involved in lipid metabolism – it is noteworthy, that a hypothesis free in 
silico study clearly links PARP-2 to lipid metabolism [54]. 
Deletion or inhibition of PARP-1 or PARP-2 impacts on lipid storage. In the white 
adipose tissue (WAT), the role of PARP-1 in triglyceride storage seems to be complex and 
has debated points. In cellular models the absence or silencing of PARP-1 leads to lower 
lipid storage in the WAT through modulating PPARγ transactivation [55, 56]. Most in vivo 
studies on PARPi-treated or PARP-1 knockout mice show, similarly to cellular studies, 
proportionally reduced WAT mass in PARPi-treated or PARP-1-/- mice [24, 32, 57], however, 
another study by Devalaraja-Narashimha and Padanilam (2010) [58]showed an inverse 
behavior of PARP-1-/- mice, namely PARP-1 knockout mice are more prone for obesity upon 
high fat feeding. PARP-2 through modulating PPARγ activity facilitates lipid deposition in the 
WAT[15]. Triglycerides can be deposited in the liver as well. The deletion of PARP-2 protects 
against hepatic lipid deposition[15], similarly to PARP-1[59, 60]. 
Besides FA and triglyceride(TG) metabolism PARP-1 and PARP-2 influence cholesterol 
metabolism too. PARP-1 was shown to repress cholesterol efflux from macrophages through 
repressing LXR that diminishes the expression of ATP-binding cassette sub-family A 
Member 1 (ABCA1) a key cholesterol export protein [27]. In hepatocytes PARP-1 together 
with histone H1.2 is necessary for the efficient transcription of microsomal epoxide hydrolase 
(EPHX1), therefore PARP-1 may have role in facilitating bile acid export from 
hepatocytes[61]. PARP-2 was shown to repress hepatic cholesterol synthesis by repressing 
SREBP-1 expression [35]. The ablation of PARP-2, similarly to PARP-1, also led to 
decreased ABCA1 mRNA and protein expression and hepatic cholesterol accumulation [35] 
that is not due to changes in ABCA1 promoter activity [35]. It is likely that other PARPs (will 
be identified to influence lipid metabolism through pathways like Tyrosine Kinase Non 
Receptor 1 (TNK1) or LXR. 
It should be noted that PARP activation and its deleterious effects seems to play 
important role in lipotoxicity. A toxic derivative of cholesterol, 7-ketocholesterol[62] can 
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activate PARP-1. Furthermore, FA-induced lipotoxicity also involves the NAD+- PARP-1 in 
hepatocytes [63]. In fact, Chen and colleagues[64] have identified ACBD3-ERK pathway to 
kick off PARP-1 activation as a result of FA treatment. Interestingly, α-lipoic acid can 
downregulate PARP-2 expression and hence exert a protective phenotype [65]. It is clear 
that the link between lipotoxicity and PARP activation is not elucidated in detail. 
 
5.2PARPs and circadian rhythm, food uptake and hormonal control 
5.2.1. Role of PARPs in circadian rhythm control 
Systemic metabolism must be able to accommodate diurnal changes (e.g. feeding cycle, 
sleeping, etc.). The molecular basis of the diurnal cycling is the cyclic transcription, 
translation and degradation of four proteins Clock, Bmal, Per and Cry over a 24 hour cycle 
that impacts on systemic metabolism. Although this oscillation has its own cycle (~24 hours) 
in the body, external stimuli (e.g. feeding, changes in lighting) or internal stimuli (e.g. 
changes in serum nutrient concentrations) are capable of resetting our circadian clock. The 
central coordinator of human diurnal rhythm oscillations is the (ventromedial) hypothalamus 
[66]. The ventromedial hypothalamus senses nutrients in the circulation and in the 
cerebrospinal fluid, furthermore receives information from other cortical regions (e.g. from 
vision). These inputs are processed and converted into vegetative outputs (e.g. 
hunger/satiety) or into hormonal signals. 
PARPs can regulate central and peripheral circadian responses. Several studies 
suggest that PARP-1 influences food uptake and feeding behavior [24, 58]. The deletion of 
PARP-1 in mice resulted in increased food uptake and altered circadian entrainment of the 
feeding behavior suggesting an impairment of the central (hypothalamic) circadian system. 
Importantly, feeding or fasting has been shown to impact on PARP-1 activity[24]. Conversely, 
deletion of PARP-2 does not alter food intake or feeding behavior [24]. 
There seems to be peripheral roles for PARP-1 in diurnal regulation. Asher and co-
workers [67] described that in mouse liver PARP-1 activity follows circadian rhythm and is 
regulated by feeding providing an important link between the peripheral circadian rhythm and 
metabolism. PARP-1 can interact with circadian proteins, PARylate CLOCK which attenuates 
the interaction with PER and CRY protein. Thereby, PARP-1 alters the expression of several 
circadian genes [67]. 
 
5.2.2. PARPs in the regulation of glucose homeostasis 
PARP-1, PARP-2, tankyrases (PARP-5a, PARP-5b) and PARP-16 have control over the 
intricate web of the hormonal regulation of glucose homeostasis through improving beta cell 
function or by regulating insulin sensitivity (Fig. 1.). 
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Pancreatic beta cells produce insulin that is the major hormone to eliminate glucose from 
the circulation. PARP-1 overactivation has major role in toxic beta cell death and PARP 
inhibition has protective role under these circumstances[15], moreover, PARP inhibition can 
even restore the function of the insulin promoter [68]. PARP-16 was shown to protect cells 
against ER stress, a major cause of beta cell dysfunction and beta cell death [69]. 
Interestingly, PARP-2 is required for beta cell function, its loss blunts beta cell proliferation 
probably through blocking pdx-1 expression[15]. Tankyrase 1 (PARP5a) is also involved in 
beta cell proliferation, its loss induces insulin secretion and beta cell proliferation[70]. It is 
also of note that PARP-1 interferes with GLP-1 signaling[71], an early signal that potentiates 
feeding-induced insulin secretion mTOR may represent additional pathways regulating beta 
cell function. 
Insulin action is also under the control of PARPs. Deletion of PARP-1 or PARP-2 
improves insulin sensitivity, similarly to short term PARP inhibition[15]. Improved insulin 
sensitivity is most probably attributed to glucose uptake into skeletal muscle driven by 
improved mitochondrial oxidation and isotype switch declutched by SIRT1 activation[15]. 
Tankyrase 1 and 2 (PARP5a, PARP5b) were shown to be involved in the insulin-induced 
Glut4 vesicle translocation in adipocytes[70]. 
 
5.2.3. PARPs and other metabolic hormones 
Interplay between PARPs and other hormonal signaling systems were also described. 
Castration and lower androgen levels decrease PARP activity in neuronal ischemia-
reperfusion injury[72]. Estradiol induces the expression of PARP-1 in the uterus [73]. These 
data implicate a correlation between estrogen signaling and PARP, and suggest that 
androgens or the androgen-to-estrogen ratios may be important for PARP activation. Finally, 
the inhibition of insulin-like growth factor (IGF)-1 signaling that induces cell death is 
potentiated by pharmacological PARP inhibition suggesting an interplay between the two 
systems[74]. 
 
6 PARP-mediated metabolic diseases 
PARPs are implicated in a plethora of metabolic or metabolism-related pathologies 
(Table 2.). It is of note that these diseases are not purely metabolic pathologies, but have 
other features as well, such as metaflammation(low grade inflammation in metabolic 
pathologies such as in obesity) or cell death (for example in type I. diabetes). PARP-1 and 
PARP-2 are considered pro-inflammatory in Th1 and Th2-regualted pathologies[15], 
moreover, PARP inhibitors can blunt inflammation in humans [75] and metaflammation in 
mice [32]; PARP-mediated cell death was discussed earlier. 
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Tumors are characterized by metabolic rearrangements that is called Warburg 
metabolism (a name taken from Otto Warburg first describing cancer-related metabolic 
changes). A hallmark of Warburg metabolism is the suppression of mitochondrial oxidation, 
while pathways that improve mitochondrial oxidative metabolism counteract the Warburg 
rearrangement of metabolism[76]. It is of note that PARP overactivation can decrease 
mitochondrial activity that is a pro-Warburg, while genetic or pharmacological PARP 
inhibition increases oxidative metabolism that is an anti-Warburg feature. 
Aging is a time-dependent functional decline characterized by numerous hallmarks (for 
review see [77]. Among the hallmarks metabolic decline is a major feature. Several studies 
have shown that PARP-1 activity increases on the course of aging (presumably due to the 
accumulating DNA damage) that decreases NAD+ content and consequently SIRT1 activity 
and mitochondrial biogenesis in metabolic tissues [78, 79]. In line with that, a mouse strain 
overexpressing an extra copy of human PARP-1 are protected against certain malignancies, 
while the incidence of age-related metabolic diseases (obesity, glucose intolerance) that is 
associated with mitochondrial dysfunction [80]. Not only insulin resistance of skeletal muscle, 
but the skeletal muscle fatigue is also related to dysregulation of SIRT1 by age-related 
PARP-1 activation [81]. Counteracting PARylation in skeletal muscle can be used to 
counteract muscle degeneration [82]. 
 
7 Conclusions 
Our vision of how PARPs integrate metabolism has greatly enlarged in the past few 
years. Although it is easy to appreciate PARP-1 and PARP-2 as enzymes integrating 
environmental stress into metabolic circuits and hence damaging those processes, it seems 
that this cannot be taken as a general rule. PARP-1 and PARP-2 has positive metabolic 
properties and minor PARP isoforms also possess beneficial metabolic features. Key 
metabolic targets of PARPs are identified such as sirtuins, mitochondria, beta cells or 
skeletal muscle, There are apparent blurry points that warrant further research (e.g. PARP-
mediated signaling pathways, metabolic diseases). A better understanding of cell/tissue or 
disease specificity of the PARP-mediated pathways will be needed. Studies on metabolome 
changes upon PARP activation/inhibition are arriving pointing towards biomarker 
identification [83, 84]. It seems there is much more to be found at the PARP – metabolism 
interface. 
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Figure caption 
Figure 1. PARP-regulated pathways in beta cells and in peripheral insulin action. 
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Tables 
Table 1. Known PARP-interacting NRs 
Nuclear receptor PARP 
partner 
Effects 
ER PARP-1/-2 PARP-1 is a positive regulator of ER. 
PARP-1 is required to reseal topoisomerase IIβ-induced DNA breaks associated with ER activation. 
Estrogen is capable of counteracting PARP activation with an unknown mechanism. 
PARP-2 does not interfere with ERβ 
PARP-2 is a positive regulator of ERα 
PR PARP-1 Progesterone stimulates PARP-1. 
PR interacts with PARP-1. 
RAR PARP-1 PARP-1 is a positive cofactor of RAR. 
TR PARP-1 PARP-1 is a positive cofactor of TR. 
PARP-1 is necessary for the activity of TR/RXR heterodimer, while its overexpression hampers nuclear receptor 
transactivation. 
RXR/PPARα PARP-1 PARP-1 PARylates and inactivates PPARα 
RXR/PPARγ PARP-1/-2 PARP-2 is a positive cofactor of the RXR/PPARγ heterodimer binding to PPARγ-mediated promoters.  
The ablation of PARP-2 leads to WAT hypofunction. 
PARP-1 is necessary for normal expression of PPARγ-mediated genes in adipocytes. 
PARP-1 overactivation hampers adiponectin expression by PARylating PPARγ. 
PARP-1 inhibition results in reduced adipose tissue inflammation in obese mice. 
PARP-1 is required for PPARγ cofactor exchange. 
RXR PARP-1 The second Zn finger of PARP-1 is the interaction surface between RXR and PARP-1. 
NOR1, 
Nur1 
PARP-1 PARP-1 is a cofactor of NOR-1 and Nur-1 transcription. PARP-1 overexpression represses NOR-1 and Nur-1 
transcription. 
AR PARP-1 PARP-1 is a positive regulator of the AR promoter. 
LXR PARP-1 
PARP-2 
PARP-7 
PARP-1 represses ABCA1 expression and cholesterol efflux in macrophages. 
PARP-2 is a positive cofactor of LXR 
PARP-7 coregulates (activates) LXR through ADP-ribosylation. 
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Table 2. PARP-mediated metabolic diseases 
 
Disease / Condition PARP(s) involved Mechanism Model / Source of evidence 
Obesity PARP-1, PARP-2 
Down-regulation of NAD+/sirtuin pathway is related to 
obesity. 
Monozygous twin study, PARP-1 knockout 
mice, PARP-2 knockout mice, PARPi 
    
Impaired PPARγ activation upon PARP-1 or PARP-2 
silencing 
PARP-1 knockout mice, PARP-2 knockout 
mice, PARP-1 and PARP-2 silencing 
Type I diabetes Not specified 
PARP inhibitors prevent diabetes by reducing β-cell 
apoptosis. Diabetes-prone NOD mouse model, PARPi 
Type II diabetes PARP-1, PARP-2 
Deletion, silencing or inhibition of PARP-1 or PARP-2 
improvesmitochondrial biogenesis and insulin sensitivity in 
the liver and skeletal muscle 
PARP-1 knockout mice, PARP-2 knockkout 
mice, PARP-1 and PARP-2 silencing in 
cellular models, PARPi studies 
  Not specified PARP activity correlates with OSA, DFU and lower IENFD . 
Cross-sectional study of adults with type 2 
diabetes 
Diabetic sequels PARP-1 
PARP-1 deletion or PARPi treatment protect against 
diabetic (micro)vascular dysfunction 
T2DM mouse model, Ex vivo model using 
mouse IMECs (MS-1 cells) 
  not specified 
PARP inhibition promotes wound healing and angiogenesis 
at ischemic wounds in diabetes FVB/NJ mouse model 
  PARP-1 
PARP-1 inhibiting flavonoids attenuate LPS-induced 
cytokine release from leukocytes. Male patients with T2D 
  not specified 
PARP inhibition ameliorates development of diabetic 
nephropathy. type 2 diabetes db/db mouse model 
  PARP-1 PARP-1 inhibition protect against diabetic oculopathy murine type 2 diabetes models 
AFLD PARP -1 
Alcohol mediated increase in PARP-1 activity and decrease 
in SIRT1 activity perturbs liver clock leading to the 
dysfunction of lipid metabolic pathways. 
PARP inhibition or the inactivation of the PARP-1 gene is 
anti-inflammatory in AFLD 
Alcohol fed mouse model 
Alcohol fed mouse model 
NAFLD PARP-1 
PARP -1 inhibition leads to increased mitochondrial 
metabolism through SIRT1 activation. 
PARP-1 knockdown mouse model 
PARP-1 knockdown mouse model 
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PPARα PARylation suppresses hepatic fatty acid oxidation. 
Toxic steatohepatitis PARP-7 
Absence of PARP7 (TiPARP) results in increased AHR 
activity due to reduced mono-ADP-ribosylation leading to 
increased dioxin sensitivity. PARP-7-/- mouse model 
PCOS PARP-1 
Negative correlation between PARP activity and PCOS 
related metabolic disorders Wistar rat model 
Atherosclerosis PARP-1, PARP-2 
PARP-1 represses LXR mediated ABCA1 expression. 
PARP-2 deletion correlates with lowered ABCA1 expression 
although the exact mechanism is unknown. 
PARP-1 knockout mice, PARP-2 knockout 
mice 
Hypercholesterolemia PARP-2 
In PARP-2-/- mice serum HDL levels decrease while LDL 
levels remains unchanged. PARP-2 knockout mice 
Hyperlipidemia PARP-1 Knockout of PARP-1 decreases serum TG and FFA levels. PARP-1 knockout mice 
Cancer cachexia PARP-1, PARP-2 
PARP-1 and PARP-2 deletion counterbalances 
downregulation of muscle-specific microRNAs ultimately 
leading to improvements in body and muscle weights of 
cachectic animals. 
PARP-1 knockout mice, PARP-2 knockout 
mice 
Hashimoto thyroiditis PARP-1 
Association only, speculated connection between PARP-1 
variants and PARP-1 regulated inflammatory response gene 
expressions Human patient study 
Aging PARP-1 
Lower PARP-1 expression improves aging-related metabolic 
pathologies. 
In vitro experiments, animal models and 
human studies 
 
 
